Who defines resistance? The clinical and economic impact of antimicrobial susceptibility testing breakpoints

Seminars in Pediatric Infectious Diseases

Volumn 15, Issue 2, 2004, Pages 105-108

  Jorgensen, James H ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; BETA LACTAM; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; GLYCOPEPTIDE; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; DATA ANALYSIS; DECISION MAKING; DRUG DOSE REGIMEN; ECONOMIC ASPECT; HUMAN; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; EUROPE; HUMANS; MICROBIAL SENSITIVITY TESTS; UNITED STATES;

EID: 3042708637     PISSN: 10451870     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.spid.2004.01.014     Document Type: Review

References (24)

1. Tenover F.C. Development and spread of bacterial resistance to antimicrobial agents. An overview. Clin Infect Dis. 15:(suppl):2001;S108-S115
2. Williams R.M. Globalization of antimicrobial resistance epidemiological challenges. Clin Infect Dis. 15:(suppl):2001;S116-S117
3. Tenover F.C., Tokars J., Swenson J., et al. Ability of clinical laboratories to detect antimicrobial-resistant enterococci. J Clin Microbiol. 31:1993;1695-1699
4. Sahm D.F., Karlowsky J.A., Kelly L.J., et al. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States 2-year longitudinal analysis. Antimicrob Agents Chemother. 45:2001;1037-1042
5. NCCLS. Analysis and presentation of cumulative antimicrobial susceptibility test data. 2003;NCCLS, Wayne, PA. Approved guideline M39-A
6. Jorgensen J.H., Ferraro M.J. Antimicrobial susceptibility testing General principles and contemporary practices. Clin Infect Dis. 26:1998;973-980
7. Jorgensen J.H. Selection criteria for an antimicrobial susceptibility testing system. J Clin Microbiol. 31:1993;2841-2844
8. Craig W.A. Qualitative susceptibility tests versus quantitative MIC tests. Diagn Microbiol Infect Dis. 16:1993;231-236
9. MacGowan A.P., Wise R. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother. 48:(suppl):2001;17-28
10. Craig B.A. Modeling approach to diameter breakpoint determination. Diagn Microbiol Infect Dis. 36:2000;193-202
11. NCCLS. Development of in vitro susceptibility testing criteria and quality control parameters. 2001;NCCLS, Wayne, PA. Approved guideline M23-A2
12. Brunden M.N., Zurenko G.E., Kapik B. Modification of the error-rate bounded classification scheme for use with two MIC breakpoints. Diagn Microbiol Infect Dis. 15:1992;135-140
13. NCCLS. Performance standards for antimicrobial disk susceptibility tests. 2003;NCCLS, Wayne, PA. Approved standard M2-A8
14. NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 2003;NCCLS, Wayne, PA. Approved standard M7-A6
15. NCCLS. Methods for antimicrobial susceptibility testing of anaerobic bacteria. 2001;NCCLS, Wayne, PA. Approved standard M11-A5
16. NCCLS. Performance standards for antimicrobial susceptibility testing. 2003;NCCLS, Wayne, PA. Supplement M100-S13
17. Craig W.A. Pharmacokinetics/pharmacodynamic parameters rationale for antibacterial dosing of mice and men. Clin Infect Dis. 26:1998;1-10
18. Drusano G.L., Preston S.L., Hardalo C., et al. Use of preclinical data for selection of a phase II/III dose for evernamicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother. 45:2001;13-22
19. Andes D.R., Craig W.A. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect Dis Clin North Am. 13:1999;595-618
20. Montgomery M.J., Beringer P.M., Aminimanizani A., et al. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 45:2001;3468-3473
21. Ferraro M.J. Should we reevaluate antibiotic breakpoints? Clin Infect Dis. 33:(suppl 3):2001;S227-S229
22. European Committee for Antimicrobial Susceptibility Testing (EUCAST). Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution. EUCAST discussion document. Clin Microbiol Infect. 6:2000;509
23. Jones M.E., Karlowsky J.A., Blosser-Middleton R., et al. Longitudinal assessment of antipneumococcal susceptibility in the United States. Antimicrob Agents Chemother. 46:2002;2651-2655
24. Jones M.E., Karlowsky J.A., Blosser-Middleton R., et al. Reinterpretation of susceptibility data using current NCCLS breakpoint criteria. Antimicrob Agents Chemother. 47:2003;830